US 12,138,276 B2
Halogenated psilocybin derivatives and methods of using
Jillian M. Hagel, Calgary (CA); and Peter J. Facchini, Calgary (CA)
Assigned to Enveric Biosciences Canada Inc., Calgary (CA)
Filed by Enveric Biosciences Canada Inc., Calgary (CA)
Filed on May 6, 2024, as Appl. No. 18/655,793.
Application 18/655,793 is a continuation of application No. 17/903,080, filed on Sep. 6, 2022, granted, now 11,998,557.
Application 17/903,080 is a continuation of application No. PCT/CA2021/051209, filed on Sep. 1, 2021.
Claims priority of provisional application 63/073,104, filed on Sep. 1, 2020.
Prior Publication US 2024/0299427 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 31/4045 (2006.01); C12N 9/02 (2006.01); C12N 9/10 (2006.01); C12N 9/12 (2006.01); C12N 15/52 (2006.01); C12P 17/10 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 31/4045 (2013.01); C12N 9/0083 (2013.01); C12N 9/1007 (2013.01); C12N 9/1205 (2013.01); C12N 15/52 (2013.01); C12P 17/10 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A chemical compound or salt thereof having the formula (I):

OG Complex Work Unit Chemistry
wherein, at least one of R2, R4, R5, R6 or R7 is a halogen atom, wherein each non-halogenated R2, R5, R6, or R7 is a hydrogen atom or an alkyl group or O-alkyl group, wherein R4 when it is not halogenated is a phosphate group, a hydrogen atom or an alkyl group or O-alkyl group, and wherein R3a and R3b are a hydrogen atom, an alkyl group, an aryl group, or an acyl group.